Novel DNA methylation biomarkers for the prognosis during the early stages of cancer, such as INHBB, SMOC2, BDNF, and TBRG4, are being tested for clinical use to improve detection methods and guide the treatment and diagnoses of cancer patients. Here, SMOC2 is linked to cancer.